Company intelligence / Profile preview
Chanceon
Hangzhou, Zhejiang, Chinachancepharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Chance Pharmaceuticals is advancing CXG87, an improved dry powder inhalation formulation of budesonide/formoterol, into Phase 3 clinical trials. The company leverages proprietary spray-drying technology to develop innovative inhaled therapies targeting unmet needs in respiratory diseases as well as CNS and fibrotic disorders. Recent funding will accelerate late-stage development.
- Therapeutic areas
- Pulmonology
- Modalities
- Small moleculeBiologicDry powder inhalation therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Strategic partnerships with domestic and international partners
Beyond the preview
Go deeper on Chanceon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chanceon.